Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo
| Autor: | Tuttle, Katherine R., Bosch-Traberg, Heidrun, Cherney, David Z.I., Hadjadj, Samy, Lawson, Jack, Mosenzon, Ofri, Rasmussen, Søren, Bain, Stephen C. |
|---|---|
| Zdroj: | In Kidney International April 2023 103(4):772-781 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|